^
BIOMARKER:

CD133 overexpression

i
Other names: RP41, AC133, CD133, MCDR2, STGD4, CORD12, PROML1, MSTP061, Prominin 1
Entrez ID:
Related biomarkers:
2d
Increased CD133 protein expression is associated with sooner distant tumor recurrence on MRI in glioblastoma patients and patients with high-grade gliomas and improved TTL on MRI in glioblastoma patients. Based on the current evidence from 1086 patients with high-grade gliomas, CD133 overexpression is a valuable marker to predict tumor relapse and tumor recurrence patterns in patients with high-grade gliomas.
Retrospective data • Review
|
CD133
|
CD133 expression • CD133 overexpression
1m
Overall, these results suggest that HDAC9 inhibition plays a functional role in the modulation of EMT properties in CSC-like prostate cancer cells. Therefore, these findings could facilitate the development of therapeutic strategies for controlling prostate cancer metastasis.
Preclinical • Journal
|
CD133 • CDH1 (Cadherin 1)
|
CDH1 expression • CD133 expression • CD133 overexpression
2ms
Interestingly, the diminution of Akt expression by specific siAkt effectively reversed suppressive activity of TDB targeting on the CSC phenotype in human lung cancer cells. These findings provide promising evidence of the inhibitory effect of TDB against lung CSCs via suppression of Akt/GSK3β/β-catenin cascade and related proteins, which would facilitate the development of this bibenzyl natural compound as a novel CSC-targeted therapeutic approach for lung cancer treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CD133 • POU5F1 (POU Class 5 Homeobox 1) • SOX2 • GSK3B (Glycogen Synthase Kinase 3 Beta) • NANOG (Nanog Homeobox)
|
CD133 expression • CD133 overexpression
4ms
High CEACAM5 expression in colorectal cancer cells is firmly associated with the CD133-positive colorectal CSC phenotype, but it is unlikely that CD133 directly regulates CEACAM5 expression.
Journal
|
CD133 • CEACAM5 (CEA Cell Adhesion Molecule 5) • S100A8 (S100 Calcium Binding Protein A8) • S100A9 (S100 Calcium Binding Protein A9)
|
CEACAM5 positive • CD133 positive • CD133 expression • CD133 overexpression • CEACAM5 expression • CEACAM5 overexpression
4ms
Moreover, the combination treatment of jorunnamycin A (0.5 μM) and cisplatin (25 μM) also diminished CD133-overexpresssing cells presented in CSC-enriched spheroids. Thus, evidence on the regulatory functions of jorunnamycin A may facilitate the development of this marine-derived compound as a novel chemotherapy agent that targets CSCs in lung cancer treatment.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CD133 • POU5F1 (POU Class 5 Homeobox 1) • SOX2 • NANOG (Nanog Homeobox)
|
CD133 expression • CD133 overexpression
|
cisplatin
6ms
Furthermore, serum deprivation increased the amount of endogenous CD133 protein, which was regulated at least in part by PI3K. Thus, it is highly likely that CD133 contributes to the acquisition/maintenance of the resistance to stress arising from nutrient deficiency in early avascular tumor tissues.
Journal
|
CD133
|
CD133 overexpression
7ms
A novel mRNA 3’UTR shortening machinery was shown to mediate the simultaneous overexpression of ABCG2 and CD133 in SP and CSC cells. It may represent useful drug target for circumvention of resistance and eradication of CSCs.
Late-breaking abstract
|
ABCG2 • CD133 • BMI1 (BMI1 proto-oncogene, polycomb ring finger)
|
ABCG2 overexpression • CD133 expression • CD133 overexpression
7ms
When Elk-1 expression is silenced, the expression of these stemness genes is decreased. We propose that Elk-1 is a transcription factor upstream of these genes, regulating the self-renewal of CD133+ BTICs.
Journal
|
CD133 • POU5F1 (POU Class 5 Homeobox 1) • SOX2 • NANOG (Nanog Homeobox)
|
CD133 expression • CD133 overexpression
7ms
More importantly, we found by RT-PCR aberrant activation and upregulation of Wnt/ β-catenin and its downstream targeting genes, such as DKK1 and AXIN2 in SP cells. These findings suggest that development of new anticancer drugs which target Wnt/β-catenin signaling might effectively exterminate the SP cells and aid in disease free survival.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • DKK1 (dickkopf WNT signaling pathway inhibitor 1) • ABCG2 • CD133
|
CD133 overexpression
9ms
Knockdown of miR-150-5p contributed to CD133- cells with stem cell-like phenotype, whereas overexpression of miR-150-5p suppressed CD133+ glioma stem cell-like characteristics. In conclusion, miR-150-5p inhibited the progression of glioma through controlling stem cell-like characteristics by regulating the Wnt/β-catenin pathway, providing a novel target for glioma treatment.
Journal
|
CD133
|
CD133 overexpression
10ms
Finally, PARK7 knockdown increased mouse survival and IR sensitivity in vivo. Based on these data, we propose that PARK7 plays a pivotal role in the maintenance of stemness and therapeutic resistance in GSCs.
Journal
|
EGFR (Epidermal growth factor receptor) • NOTCH1 (Notch 1) • CD133 • POU5F1 (POU Class 5 Homeobox 1) • SOX2
|
CD133 overexpression
11ms
The nanoparticles could be used as a T2-weighted magnetic resonance imaging contrast media, and also applied during hyperthermia and chemotherapy to display a synergistic anticancer effect. Therefore, the superparamagnetic iron oxide@poly(sodium styrene sulfonate)/irinotecan/human serum albumin-anti-CD133 nanoparticles are a powerful candidate for future antitumor strategies.
Journal
|
CD133
|
CD133 expression • CD133 overexpression
|
irinotecan
11ms
Thus, although CSCs 5-FU chemoresistance appears to be independently to MMR status, hMLH1 might play a key role in CSC response to 5-FU. New drugs exploding these differences could benefit the prognostic of patients with CRC.
Journal
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CD133
|
CD133 expression • CD133 overexpression • MSH6 expression
|
fluorouracil topical
12ms
Lenalidomide also enhanced the cytotoxicity against MDA-MB-453 and the cytokine secretion of HER2-CAR T cells but did not affect their proliferation significantly. Furthermore, lenalidomide may regulate the function of CAR T cells by inducing the degradation of transcription factors Ikaros and Aiolos.
Journal • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • CD133
|
CD133 overexpression
|
Revlimid (lenalidomide)